Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Purity: Advanced Purification Strategies, Analytical Methods, And Quality Control For Pharmaceutical And Research Applications

NOV 17, 202652 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine Phosphate Purity represents a critical quality parameter in pharmaceutical manufacturing, clinical applications, and biochemical research. Achieving high-purity creatine phosphate (typically ≥98.0% by HPLC) requires sophisticated purification techniques that effectively remove organic impurities (creatine, creatinine, creatine anhydride), inorganic contaminants (phosphate salts, metal ions), and nucleotide residues (ATP, ADP, AMP). This article provides an in-depth analysis of state-of-the-art purification methodologies, quantitative analytical protocols, and quality assurance frameworks essential for producing pharmaceutical-grade creatine phosphate sodium suitable for injectable formulations and high-precision research.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Structural Characteristics Of Creatine Phosphate

Creatine phosphate (N-phosphorylcreatine, phosphocreatine) exists predominantly as the disodium salt tetrahydrate (C₄H₈N₃O₅PNa₂·4H₂O, molecular weight 327.15 for the anhydrous form) in pharmaceutical preparations 1. The compound features a phosphoramidate bond linking the phosphate group to the guanidino nitrogen of creatine, rendering it susceptible to hydrolysis under acidic conditions or elevated temperatures. In aqueous alkaline media (pH 9–12), creatine phosphate undergoes reversible cyclization to form creatine anhydride phosphate (creatinine phosphate), a key intermediate exploited in several purification strategies 12. The zwitterionic nature of creatine phosphate at physiological pH (isoelectric point ~6.5) governs its chromatographic behavior and crystallization properties.

Key physicochemical parameters influencing purity assessment include:

  • Spectroscopic signature: Maximum UV absorption at 210 nm (ε ~9,800 M⁻¹cm⁻¹), enabling HPLC quantification with detection limits <0.01% for related substances 24
  • Thermal stability: Decomposition onset at 180–200°C (TGA), with accelerated degradation above 60°C in aqueous solution 1
  • Hygroscopicity: Rapid water uptake (4–6% w/w) under ambient conditions, necessitating Karl Fischer titration for accurate purity determination 3
  • Solubility profile: Highly soluble in water (>400 mg/mL at 25°C), sparingly soluble in methanol, insoluble in ethanol and acetone—properties critical for crystallization-based purification 14

The presence of structural analogs such as cyclocreatine phosphate and homocyclocreatine phosphate has been documented in synthetic preparations, requiring chromatographic resolution for pharmaceutical compliance 1213.

Advanced Purification Methodologies For High-Purity Creatine Phosphate Sodium

Alkaline Cyclization-Hydrolysis Route For Organic Impurity Removal

A breakthrough purification strategy leverages the reversible cyclization of creatine phosphate to creatinine phosphate under strongly alkaline conditions 12. The process comprises three sequential steps:

  1. Cyclization phase: Crude creatine phosphate sodium (HPLC purity 85–92%) is dissolved in 4–6 M NaOH at 0–5°C, promoting quantitative conversion to creatinine phosphate sodium within 30–60 minutes 1. This step effectively separates lipophilic impurities (unreacted creatine phosphoryl chloride derivatives) into the organic phase during subsequent ethyl acetate extraction.

  2. Crystallization of cyclic intermediate: Addition of ethanol (3–4 volumes) to the alkaline aqueous phase induces crystallization of creatinine phosphate sodium with >95% recovery 1. Filtration at 0–10°C removes water-soluble salts (NaCl, sodium carboxylates) and residual nucleotides.

  3. Hydrolytic ring-opening: The purified creatinine phosphate sodium is redissolved in water and treated with dilute NaOH (pH 11–12) at 40–60°C for 2–4 hours, regenerating creatine phosphate sodium 12. Neutralization with organic acids (acetic, isooctanoic) to pH 7.0–7.5, followed by ethanol precipitation, yields creatine phosphate sodium with HPLC purity ≥99.8% and creatine/creatinine content <0.1% 1.

This method achieves molar yields of 43.7% (based on starting creatinine) and eliminates the need for toxic barium salts or heavy metal catalysts, ensuring compliance with ICH Q3D elemental impurity guidelines 1.

Multi-Stage Ion-Exchange Chromatography For Enzymatic Synthesis Products

For creatine phosphate produced via enzymatic phosphorylation (creatine kinase-catalyzed transfer from ATP or phosphoenolpyruvate), ion-exchange purification provides superior resolution of charged impurities 39. A representative protocol involves:

  • Cation exchange pre-treatment: Crude reaction mixture (pH adjusted to 9.5–11.0) is passed through strong acid cation resin (e.g., Amberlite IR-120, H⁺ form) to remove Mg²⁺, Mn²⁺, and residual enzyme 3. This step reduces metal ion content to <5 ppm.

  • Weak anion exchange: The effluent is loaded onto a weak base resin (e.g., Amberlite IRA-67, free base form) at 4–8°C, where creatine phosphate binds while neutral creatine and creatinine pass through 3. Elution with 0.2–0.5 M NaCl gradient separates creatine phosphate from monobasic phosphate salts.

  • Strong anion exchange polishing: Final purification on a strong base resin (e.g., Dowex 1×8, Cl⁻ form) with 0.5–0.8 M NaCl elution removes trace ADP/AMP (retention time difference ~3 min under isocratic conditions) 34. Nanofiltration (MWCO 200–500 Da) concentrates the eluate 5–10 fold prior to ethanol precipitation.

This cascade achieves >90% recovery with final purity ≥98.5% (HPLC area normalization) and phosphate impurity content <0.02% (evaporative light scattering detection) 34. The method is scalable to 100 L batches with consistent performance across enzymatic feedstocks containing 30–150 mM creatine phosphate 3.

Preparative HPLC For Ultra-High Purity Standards

Medium-pressure preparative chromatography on C18 stationary phases enables production of reference standards with purity >99.9% 7. Optimized conditions include:

  • Column specifications: YMC C18 (10 μm particle size, 30×250 mm) maintained at 3–8°C to minimize on-column degradation 7
  • Mobile phase: Methanol–200 mM phosphate buffer (pH 7.0, containing 5 mM tetrabutylammonium bromide as ion-pairing agent) at 15:85 v/v, flow rate 40–50 mL/min 7
  • Sample loading: 5 mL injections of 40–50 mg/mL creatine phosphate disodium (degassed with nitrogen), collecting fractions with peak height >1500 mV at 259 nm 7
  • Post-chromatographic processing: Pooled fractions undergo sodium ion equilibration with 8% methanol–10 mM sodium phosphate (pH 6.0) to exchange residual tetrabutylammonium, followed by desalting on the same column with 2 L of equilibration buffer 7

Lyophilization of the desalted eluate yields creatine phosphate trisodium with water content 8–12% (Karl Fischer) and organic purity 99.95% (HPLC with diode array detection, 200–400 nm scan) 7. This material serves as a primary standard for calibrating routine analytical methods.

Quantitative Analytical Methods For Creatine Phosphate Purity Assessment

High-Performance Liquid Chromatography With Multi-Wavelength Detection

HPLC remains the gold standard for creatine phosphate purity determination, with method validation parameters meeting USP <621> requirements 234. A widely adopted protocol employs:

  • Stationary phase: Octadecylsilane (C18) bonded silica, 5 μm, 250×4.6 mm, with guard column 24
  • Mobile phase: 200 mM sodium phosphate buffer (pH 7.0, adjusted with 1 M NaOH)–methanol (95:5 v/v for creatine phosphate analysis; 85:15 v/v for related substances) 47
  • Detection: Dual-wavelength monitoring at 210 nm (creatine phosphate, creatine, creatinine) and 259 nm (adenine nucleotides) 27
  • Quantification: External standard method with five-point calibration (0.1–2.0 mg/mL), linear regression r² >0.9995 3

Typical retention times: creatine (3.2 min), creatinine (4.8 min), creatine phosphate (6.5 min), AMP (9.1 min), ADP (11.3 min), ATP (14.7 min) under isocratic conditions at 35°C 27. Area normalization calculates creatine phosphate content, with correction for water (Karl Fischer) and inorganic ash (sulfated ash, <0.5%) 37:

Creatine Phosphate Purity (%) = (100% – Water Content – Ash Content) × HPLC Area%

Method precision: RSD <0.5% for six replicate injections; accuracy: 98.5–101.5% recovery in spiked samples 3.

Evaporative Light Scattering Detection For Non-Chromophoric Impurities

Phosphate salts (KH₂PO₄, Na₂HPO₄) and other inorganic impurities lacking UV chromophores require evaporative light scattering detection (ELSD) 4. The method involves:

  • Chromatographic separation: Same C18 column and mobile phase as UV-HPLC, but with ELSD parameters: nebulizer temperature 45°C, gas pressure 350 kPa (nitrogen) 4
  • Calibration: Potassium dihydrogen phosphate standards (0.5–10 μg/mL) establish response curves (log-log plot, slope ~1.3) 4
  • Limit of detection: 0.002% (w/w) phosphate relative to 2 mg/mL creatine phosphate sample 4

Samples meeting pharmaceutical specifications show no detectable phosphate peaks (retention time ~5.2 min) when analyzed at 2 mg/mL concentration 4.

Spectroscopic Orthogonal Methods

Complementary techniques validate HPLC results and detect structural anomalies:

  • UV-Vis spectrophotometry: Absorbance ratio A₂₁₀/A₂₆₀ = 4.2–4.6 for pure creatine phosphate; deviations indicate nucleotide contamination 2
  • Infrared spectroscopy: Characteristic bands at 1650 cm⁻¹ (C=N stretch), 1210 cm⁻¹ (P=O stretch), 980 cm⁻¹ (P–O–C stretch) confirm structural integrity 2. Comparison with reference spectra (correlation coefficient >0.98) ensures identity.
  • ³¹P NMR spectroscopy: Single resonance at δ 2.5–3.0 ppm (relative to 85% H₃PO₄) with no signals from inorganic phosphate (δ 0 ppm) or pyrophosphate (δ -5 to -10 ppm) 9

Quality Control Frameworks And Regulatory Compliance For Creatine Phosphate Purity

Pharmacopeial Standards And Acceptance Criteria

Pharmaceutical-grade creatine phosphate sodium must comply with monographs in major pharmacopeias, which specify:

  • Assay (anhydrous basis): 97.0–102.0% of labeled amount (HPLC, external standard) 3
  • Related substances: Individual impurity ≤0.5%, total impurities ≤2.0% (HPLC area%) 23
    • Creatine: ≤0.3%
    • Creatinine: ≤0.2%
    • Inorganic phosphate: ≤0.1% (ELSD or ion chromatography)
    • Adenine nucleotides (ATP+ADP+AMP): ≤0.5% 34
  • Heavy metals: Pb ≤2 ppm, As ≤1 ppm (ICP-MS) 1
  • Residual solvents: Methanol ≤3000 ppm, ethanol ≤5000 ppm (GC-headspace) 1
  • Bacterial endotoxins: <0.5 EU/mg (LAL test for injectable formulations) 2

Batch release testing includes stability-indicating assays (forced degradation at pH 2, pH 12, 60°C, UV light) demonstrating ≥95% recovery after 7 days 2.

Process Analytical Technology (PAT) For Real-Time Monitoring

Implementation of in-line Raman spectroscopy during crystallization enables real-time purity tracking 1. Multivariate calibration models (partial least squares regression) correlate spectral features (C=N stretch at 1650 cm⁻¹, phosphate symmetric stretch at 980 cm⁻¹) with offline HPLC data, achieving prediction errors <1.5% across 92–99% purity range 1. This approach reduces batch analysis time from 8 hours to <30 minutes, facilitating adaptive process control.

Case Study: Validation Of Enzymatic Synthesis Purification Train

A commercial-scale validation (3×100 L batches) of the ion-exchange protocol 3 demonstrated:

  • Consistency: Purity 98.2 ± 0.3% (mean ± SD, n=3), creatine content 0.18 ± 0.05%, phosphate <0.02% 3
  • Yield reproducibility: 91.2 ± 2.1% molar recovery from enzymatic feedstock containing 150 mM creatine phosphate 3
  • Impurity profile: No detectable ATP/ADP/AMP by HPLC-UV (LOD 0.01%), confirming effective nucleotide removal 3
  • Stability: Accelerated storage (40°C/75% RH, 6 months) showed <2% degradation, meeting ICH Q1A guidelines 3

This dataset supported regulatory approval for a sterile powder injectable (1 g/vial) in multiple jurisdictions.

Applications Requiring Ultra-High Creatine Phosphate Purity

Pharmaceutical Injectable Formulations For Myocardial Protection

Creatine phosphate sodium injections (0.5–2.0 g/dose) are clinically employed in acute myocardial infarction and cardiac surgery to preserve ATP levels during ischemia 1011. Purity requirements are stringent due to:

  • Dose magnitude: Daily doses up to 4–6 g necessitate impurity loads <100 mg/day to avoid toxicity 1
  • Intravenous route: Direct systemic exposure demands absence of pyrogenic substances (<0.5 EU/mg endotoxin) and particulates (≤25 particles >10 μm per container) 2
  • Hemodynamic effects: Trace adenine nucleotides (>0.5%) can cause vasodilation or arrhythmias
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
ZHONGSHAN BELLING BIOTECHNOLOGY CO. LTD.Pharmaceutical injectable formulations for myocardial protection in acute myocardial infarction and cardiac surgery requiring ultra-high purity (≥98.0%) and absence of heavy metal contamination.High-Purity Creatine Phosphate Sodium InjectableAchieved HPLC purity of 99.8% and content of 99.5% with 43.7% molar yield through alkaline cyclization-hydrolysis route, eliminating heavy metal residues and toxic barium salts for enhanced clinical safety.
CHONGQING SHENGHUAXI PHARMACEUTICAL CO. LTD.Sterile powder injectable formulations (1g/vial) for intravenous administration in cardiovascular therapy requiring stringent endotoxin control (<0.5 EU/mg) and high chemical purity.Creatine Phosphate Sodium Sterile PowderPurification via alkaline cyclization to creatinine phosphate sodium followed by hydrolytic ring-opening achieves effective removal of organic impurities (creatine, creatinine <0.3%) and inorganic contaminants, meeting pharmacopeial standards for sterile powder injectables.
安徽古特生物科技有限公司High-precision biochemical research and pharmaceutical-grade production requiring removal of enzymatic reaction byproducts, nucleotides, and metal catalysts from creatine kinase-catalyzed phosphorylation processes.Enzymatic Synthesis Creatine Phosphate SodiumMulti-stage ion-exchange chromatography purification achieves >90% recovery with final purity ≥98.5%, effectively removing nucleotide impurities (ATP/ADP/AMP <0.01%) and metal ions (<5 ppm) from enzymatic synthesis products.
XINAN PHARMACEUTICAL CO. LTD.Injectable pharmaceutical preparations requiring ultra-high purity standards with complete removal of adenine nucleotides for cardiovascular and neuromuscular disorder treatments.Pharmaceutical-Grade Creatine Phosphate SodiumIon-exchange purification with ethanol pre-treatment achieves 99.80% purity with 40% recovery rate, eliminating ATP-series substances and ensuring compliance with USP <621> requirements without introducing sulfate or barium contamination.
XENOPORT INC.Treatment of ischemia, heart failure, and neurodegenerative disorders requiring enhanced tissue penetration and cellular energy metabolism support in conditions with compromised ATP production.Membrane Permeable Creatine Phosphate ProdrugsDevelopment of membrane permeable prodrug formulations including cyclocreatine phosphate and homocyclocreatine phosphate analogs enabling enhanced cellular uptake and energy homeostasis in tissues with improved bioavailability.
Reference
  • Novel method for preparing high-purity creatine phosphate sodium
    PatentActiveCN102558227B
    View detail
  • Phosphocreatine disodium purification method and preparation method of phosphocreatine disodium aseptic powder
    PatentActiveCN106279267A
    View detail
  • A purification method for sodium creatine phosphate
    PatentActiveCN110294775B
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png